Skip to content

Fresenius Medical Care expects continued strong growth – Shareholders approve 15th consecutive dividend increase

| Press release

Fresenius Medical Care, the world’s largest provider of dialysis products and services, expects another record result for 2012. At the annual general meeting in Frankfurt am Main today, Dr. Ben Lipps, the company’s chief executive officer, confirmed the full-year outlook. Fresenius Medical Care expects revenue to grow to around $14 billion in 2012. Net income is expected to grow to around $1.3 billion and net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to grow to around $1.14 billion.

“Our stakeholders can be proud that their company is indeed making a difference in patients’ lives with our superior products and clinical services, and through our innovative research into new treatment modalities and reimbursement concepts,’’ Dr. Lipps said in his speech to the meeting. “Fresenius Medical Care has retained its global leadership position and we continue to shape the future of the dialysis industry. We have the ability to grow through the expansion of our clinic network and of our product portfolio, and by adding new services.’’

It was the last Fresenius Medical Care annual general meeting under Dr. Lipps’ leadership: The company announced in March that Rice Powell has been appointed to take over as CEO on January 1, 2013, when Dr. Lipps will retire from the Management Board and become the Supervisory Board’s Honorary Chairman.

With a large majority of 99.89% the shareholders approved the company’s 15th consecutive increase in dividend, which was raised to €0.69 from €0.65 per ordinary share and to €0.71 from €0.67 per preference share.

Shareholders approved the actions taken and decisions made by the Supervisory Board and the Management Board with a majority of more than 99%.

At the annual general meeting, 76.94% of the subscribed capital was represented. Only ordinary-share holders were entitled to vote.


Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.1 million individuals worldwide. Through its network of 3,119 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 253,041 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.